1061357-89-8

Basic information

• Product Name: 2-Bromo-5-fluoro-4-iodopyridine
• Synonyms: 2-Bromo-5-fluoro-4-iodopyridine
• CAS NO: 1061357-89-8
• Molecular Formula: C₅H₂BrFIN
• Molecular Weight: 301.8829532
• Mol File: 1061357-89-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 266.8±40.0 °C(Predicted)
• Appearance: /
• Density: 2.412±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: -3.02±0.18(Predicted)
• CAS DataBase Reference: 2-Bromo-5-fluoro-4-iodopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-fluoro-4-iodopyridine(1061357-89-8)
• EPA Substance Registry System: 2-Bromo-5-fluoro-4-iodopyridine(1061357-89-8)

Safety Data

• Hazardous Substances Data: 1061357-89-8(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-fluoro-4-iodopyridine is an organohalide compound that is also considered as an aromatic halide. It is particularly known for its three halogens, bromine, fluorine and iodine which are bound to a Pyridine ring - a basic heterocyclic organic compound with the chemical formula C5H5N. It exhibits unique chemical properties based on the presence of these halogens, and due to its structure, it can be used for various applications in medicinal chemistry and material science. Like many chemical compounds, detailed handling and risk information should be known to avoid hazards, as it may be irritating to eyes, respiratory system, and skin.

Upstream product

• 41404-58-4 2-bromo-5-fluoropyridine 
• 357927-50-5 2-bromo-4-fluoro-pyridine 

Downstream Products

• 1309880-27-0 C₂₄H₂₉FN₆O₂ 

Relevant articles and documents

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Boron Containing PDE4 Inhibitors

The present invention relates to boron containing compounds of Formula (I) [in-line-formulae]X—Y—Z?? Formula (I)[/in-line-formulae] that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.